Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

39.50 +0.82 (+2.12%)
Streaming Delayed Price Updated: 1:21 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Check Out What Whales Are Doing With CRSP
Via Benzinga
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential. 
Via InvestorPlace
Cathie Wood Has 37% of Her Ark Invest Portfolio Invested in These 7 Stocks
The famous investor owns some huge winners -- and big losers, too. 
Via The Motley Fool
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Via Benzinga
Got $100? 2 Top Cathie Wood Stocks to Buy and Hold.
These stocks are steals right now. 
Via The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector. 
Via InvestorPlace
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
2 Healthcare Stocks to Buy Hand Over Fist in February
Both companies are proven innovators. 
Via The Motley Fool
Cathie Wood Just Bought These 3 Biotech Stocks. Should You?
They aren't all long shots, but they're all innovative. 
Via The Motley Fool
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
CRISPR Therapeutics shares have soared 39% over the past three months. 
Via The Motley Fool
2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios
These two Cathie Wood holdings are great long-term buys. 
Via The Motley Fool
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio. 
Via InvestorPlace
Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. (NASDAQ: SGRY). "That industry has been up and down and up and down," he added. 
Via Benzinga
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
Bull markets generally favor growth stocks, so now is a great time to buy quality growth players. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is CRISPR Therapeutics a Buy in the New Bull Market?
CRISPR Therapeutics is a specialist in the hot technology of gene editing. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
Wood added to her existing positions in these three exciting companies. 
Via The Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions. 
Via InvestorPlace
These 5 growth stocks are now in buy ranges
Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs. 
Via MarketBeat
Topics ETFs
Where Will CRISPR Therapeutics Be in 5 Years?
The company could maintain the momentum it gained last year. 
Via The Motley Fool
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
Despite A bump in the road, the biotech's future looks sunny. 
Via The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
Has investing in Vertex been a better option than just putting your money in the S&P 500? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase. 
Via Investor's Business Daily
Topics ETFs
Could Editas Medicine Become the Next CRISPR Therapeutics?
The similarities between the pair are striking, but it might not be enough. 
Via The Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Both companies are going to continue doing high-impact science in 2024. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.